Suppr超能文献

初治糖尿病性黄斑水肿视力预后的预测因素:临床研究“FOVEA”的初步结果

Predictive Factors of Visual Outcome in Treatment-Naïve Diabetic Macular Edema: Preliminary Results from the Clinical Study "FOVEA".

作者信息

Serra Rita, Coscas Florence, Boulet Jean François, Cabral Diogo, Tran Thi Ha Chau, Solinas Giuliana, Pinna Antonio, Lupidi Marco, Coscas Gabriel

机构信息

Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy.

Istituto di Ricerca Genetica e Biomedica (IRGB), CNR, Cittadella Universitaria di Cagliari, 09042 Monserrato, Italy.

出版信息

J Clin Med. 2023 Jun 6;12(12):3870. doi: 10.3390/jcm12123870.

Abstract

UNLABELLED

Diabetic macular edema (DME) is a common cause of vision impairment in diabetic retinopathy. The aim of this study was to analyze the relationship between visual outcome and anatomic changes detected by traditional multimodal retinal imaging and optical coherence tomography angiography (OCTA) in DME eyes under treatment with Aflibercept.

METHODS

Sixty-six DME eyes of 62 patients under treatment with intravitreal Aflibercept and with one-year follow-up were enrolled. All participants underwent a full ophthalmic evaluation, including best correct visual acuity (BCVA) measurement, spectral-domain optical coherence tomography, fluorescein angiography and OCTA, both at baseline and final examination. Fractal OCTA analysis of the superficial and deep capillary plexus (SCP and DCP) was performed to estimate vascular perfusion density and lacunarity (LAC).

RESULTS

At the final examination, there was a significant improvement in terms of BCVA and central macular thickness (CMT). Furthermore, eyes with CMT <373 µm at baseline reached the higher BCVA at the last follow-up. Eyes with CMT ≥373 µm and DCP LAC <0.41 reached a higher final BCVA, if compared with eyes showing the same CMT but higher initial LAC.

CONCLUSION

A 12-month treatment with intravitreal Aflibercept for DME resulted in significant visual and anatomic improvement. Multimodal retinal imaging, together with fractal OCTA analysis, may provide useful biomarkers, predictive of visual outcome in DME.

摘要

未标注

糖尿病性黄斑水肿(DME)是糖尿病视网膜病变中视力损害的常见原因。本研究的目的是分析在接受阿柏西普治疗的DME眼中,传统多模态视网膜成像和光学相干断层扫描血管造影(OCTA)检测到的视觉结果与解剖学变化之间的关系。

方法

纳入62例接受玻璃体内阿柏西普治疗且随访一年的66只DME眼。所有参与者在基线和最终检查时均接受了全面的眼科评估,包括最佳矫正视力(BCVA)测量、光谱域光学相干断层扫描、荧光素血管造影和OCTA。对浅表和深层毛细血管丛(SCP和DCP)进行分形OCTA分析,以估计血管灌注密度和间隙度(LAC)。

结果

在最终检查时,BCVA和中心黄斑厚度(CMT)有显著改善。此外,基线时CMT<373 µm的眼睛在最后一次随访时达到了更高的BCVA。与CMT相同但初始LAC较高的眼睛相比,CMT≥373 µm且DCP LAC<0.41的眼睛最终BCVA更高。

结论

玻璃体内注射阿柏西普治疗DME 12个月可显著改善视力和解剖结构。多模态视网膜成像与分形OCTA分析一起,可能提供有用的生物标志物,预测DME的视觉结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c726/10299144/1851763000c2/jcm-12-03870-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验